soul trial oral semaglutide cardiovascular outcomes 2024 nejm 2025 results The (Semaglutide Trial) was a randomized ADA 2025: Oral Semaglutide Demonstrates – Michael Albert, MD on X:

PMID: 34934897 Konijeti, G.G., et al

For patients using GLP-1 medications for type 2 diabetes, hemoglobin A1c may increase after discontinuation if no alternative therapy is initiated, with the magnitude varying based on individual factors and baseline therapy

benefits There have been many positive effects noted by those who have experimented with the use of BPC-157 for issues including bone healing, ligament healing, general regenerative properties and more

Other findings from this study show that semaglutide reduces binge drinking in a dose-dependent manner, meaning higher doses of semaglutide lead to greater reductions in binge alcohol intake